JP2021506898A - ニコチンアミドリボシドクロリドの結晶形態 - Google Patents
ニコチンアミドリボシドクロリドの結晶形態 Download PDFInfo
- Publication number
- JP2021506898A JP2021506898A JP2020534265A JP2020534265A JP2021506898A JP 2021506898 A JP2021506898 A JP 2021506898A JP 2020534265 A JP2020534265 A JP 2020534265A JP 2020534265 A JP2020534265 A JP 2020534265A JP 2021506898 A JP2021506898 A JP 2021506898A
- Authority
- JP
- Japan
- Prior art keywords
- subject
- crystalline form
- sleep
- administering
- crystal form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/048—Pyridine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762609512P | 2017-12-22 | 2017-12-22 | |
| US62/609,512 | 2017-12-22 | ||
| PCT/US2018/066769 WO2019126482A1 (en) | 2017-12-22 | 2018-12-20 | Crystalline forms of nicotinamide riboside chloride |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021506898A true JP2021506898A (ja) | 2021-02-22 |
| JP2021506898A5 JP2021506898A5 (cg-RX-API-DMAC7.html) | 2021-11-18 |
Family
ID=66993830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020534265A Pending JP2021506898A (ja) | 2017-12-22 | 2018-12-20 | ニコチンアミドリボシドクロリドの結晶形態 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11414407B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3727400A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2021506898A (cg-RX-API-DMAC7.html) |
| CN (1) | CN112020363A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3086535A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019126482A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11129843B2 (en) | 2017-04-24 | 2021-09-28 | Elysium Health, Inc. | Treating and preventing kidney damage |
| EP3727400A4 (en) | 2017-12-22 | 2021-10-20 | Elysium Health, Inc. | CRYSTALLINE FORMS OF NICOTINAMIDE RIBOSIDE CHLORIDE |
| JP7675061B2 (ja) | 2019-07-19 | 2025-05-12 | バイオシント アクチェンゲゼルシャフト | ニコチンアミドリボフラノシド塩の製造方法、ニコチンアミドリボフラノシド塩自体、およびその使用 |
| CN111454311B (zh) | 2020-04-03 | 2021-10-19 | 深圳市迪克曼科技开发有限公司 | 烟酰胺核糖的有机酸盐及其组合物与制备方法 |
| CN111808156A (zh) * | 2020-07-15 | 2020-10-23 | 许昌远志生物科技有限公司 | 一种β-烟酰胺核糖氯化物的晶型1A、晶型1B及其制备方法 |
| EP4727544A2 (en) | 2023-06-14 | 2026-04-22 | Chromadex Inc. | Nicotinamide riboside and derivatives thereof in intravenous formulations and methods of use thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016014927A2 (en) * | 2014-07-24 | 2016-01-28 | W.R. Grace & Co.-Conn. | Crystalline form of nicotinamide riboside |
| WO2016144660A1 (en) * | 2015-03-09 | 2016-09-15 | W.R. Grace & Co.-Conn. | Crystalline form of nicotinamide riboside |
| JP2017518306A (ja) * | 2014-06-02 | 2017-07-06 | グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited | 結晶性β−D−ニコチンアミドリボシドの製造および使用 |
| WO2017218580A1 (en) * | 2016-06-14 | 2017-12-21 | Rejuvenation Therapeutics Corporation | Synthetic methods for the preparation of nicotinamide riboside and related compounds |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1190080A (en) | 1966-08-08 | 1970-04-29 | Kyowa Hakko Kogyo Company Ltd | Process for producing Nicotinamide Adenine Dinucleotide |
| US3728111A (en) | 1971-09-21 | 1973-04-17 | Asea Ab | Method of manufacturing billets from powder |
| EP0981534B1 (en) | 1997-02-06 | 2006-05-03 | Inspire Pharmaceuticals, Inc. | Dinucleotides and their uses |
| GB9712370D0 (en) | 1997-06-14 | 1997-08-13 | Aepact Ltd | Therapeutic systems |
| JP2005502580A (ja) | 2000-12-15 | 2005-01-27 | フアーマセツト・リミテツド | フラビウィルス感染治療用抗ウィルス薬 |
| US7179791B2 (en) | 2001-01-11 | 2007-02-20 | Duke University | Inhibiting GS-FDH to modulate NO bioactivity |
| JP3748536B2 (ja) | 2001-02-09 | 2006-02-22 | 三共株式会社 | ピリミジンヌクレオシド誘導体の結晶 |
| US6627646B2 (en) * | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
| US7977049B2 (en) | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| US20050020587A1 (en) | 2003-07-25 | 2005-01-27 | Pfizer Inc | Nicotinamide derivatives useful as PDE4 inhibitors |
| US8017634B2 (en) | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
| US8114626B2 (en) | 2004-02-10 | 2012-02-14 | Trustees Of Dartmouth College | Yeast strain and method for using the same to produce nicotinamide riboside |
| EP1723227A4 (en) | 2004-02-10 | 2007-09-19 | Dartmouth College | NICOTINAMIDRIBOSIDE KINASE COMPOSITIONS AND METHOD FOR THEIR USE |
| CN1964627B (zh) | 2004-06-04 | 2011-10-19 | 华盛顿大学 | 治疗神经病变的方法和组合物 |
| ES2430569T3 (es) | 2005-02-18 | 2013-11-21 | Astrazeneca Ab | Compuestos antibacterianos derivados de piperidina |
| EP2805719A1 (en) | 2005-03-30 | 2014-11-26 | Glaxosmithkline LLC | Nicotinamide riboside and analogues thereof |
| US20070149466A1 (en) | 2005-07-07 | 2007-06-28 | Michael Milburn | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
| WO2007061798A2 (en) | 2005-11-18 | 2007-05-31 | Cornell Research Foundation, Inc. | Nicotinoyl riboside compositions and methods of use |
| US20070248590A1 (en) | 2005-12-02 | 2007-10-25 | Sirtris Pharmaceuticals, Inc. | Modulators of CDC2-like kinases (CLKS) and methods of use thereof |
| WO2007136744A1 (en) | 2006-05-19 | 2007-11-29 | The Johns Hopkins University | Crystal structure of a substrate complex of nampt/pbef/visfatin |
| JP2010513458A (ja) | 2006-12-19 | 2010-04-30 | ファイザー・プロダクツ・インク | H−pgdsの阻害剤としてのニコチンアミド誘導体、およびプロスタグランジンd2の仲介による疾患を治療するためのその使用 |
| CA2676609A1 (en) | 2007-01-26 | 2008-07-31 | Washington University | Methods and compositions for treating neuropathies |
| EP2307378A1 (en) | 2008-06-18 | 2011-04-13 | Pfizer Limited | Nicotinamide derivatives |
| US20100015072A1 (en) | 2008-06-30 | 2010-01-21 | Christopher Polla | Topical Compositions Comprising Isonicotinamide |
| CL2009002206A1 (es) | 2008-12-23 | 2011-08-26 | Gilead Pharmasset Llc | Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales. |
| JP5739415B2 (ja) | 2009-05-12 | 2015-06-24 | ブリストル−マイヤーズ スクウィブ カンパニー | (S)−7−([1,2,4]トリアゾロ[1,5−a]ピリジン−6−イル)−4−(3,4−ジクロロフェニル)−1,2,3,4−テトラヒドロイソキノリンの結晶形態およびその使用 |
| WO2011005289A2 (en) | 2009-06-23 | 2011-01-13 | President And Fellows Of Harvard College | Methods and kits for measuring enzyme activity |
| WO2011011721A2 (en) | 2009-07-24 | 2011-01-27 | Amazentis Sa | Compounds, compositions and methods for protecting brain health in neurodegenerative disorders |
| US8507251B2 (en) | 2009-09-28 | 2013-08-13 | Robert J. Greenstein | Medium and method for culturing Mycobacterium avium subspecies paratuberculosis |
| WO2011081942A1 (en) | 2009-12-14 | 2011-07-07 | Cornell University | Activation and activators of sirt5 |
| EP2464249B1 (de) | 2010-03-29 | 2013-03-13 | Johannes Huber | Konzentrationssteigerndes getränk |
| US8481711B2 (en) | 2010-07-06 | 2013-07-09 | Hidenori Kamanishi | Neurite outgrowth agent |
| WO2012114204A2 (en) | 2011-02-15 | 2012-08-30 | Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto | Methods of treating mitochondrial dysfunction |
| US20120107888A1 (en) | 2011-02-17 | 2012-05-03 | Qteros, Inc. | Modulation of fermentation products through vitamin supplementation |
| US20120328526A1 (en) | 2011-06-27 | 2012-12-27 | University Of Maryland, Baltimore | Modulation of Nad+ Activity in Neuropathophysiological Conditions and Uses Thereof |
| EP3345901A3 (en) | 2011-06-29 | 2018-09-12 | President and Fellows of Harvard College | Small molecules as antiaging agents |
| US20140256760A1 (en) | 2012-07-09 | 2014-09-11 | Noglo Llc | Reduction or prevention of alcohol reaction with dietary supplements |
| EP2869717B8 (en) | 2012-07-09 | 2018-07-25 | NoGlo, Inc. | Prevention of alcohol reaction with dietary supplements |
| EP2872128B1 (en) | 2012-07-16 | 2020-02-19 | Cornell University | Nicotinamide riboside to treat hearing loss |
| WO2014059029A1 (en) | 2012-10-09 | 2014-04-17 | President And Fellows Of Harvard College | Treatment of age-related and mitochondrial diseases by inhibition of hif-1 alpha function |
| WO2014111906A1 (en) | 2013-01-21 | 2014-07-24 | Ecole Polytechnique Federale De Lausanne (Epfl) | Bioluminescence imaging of small biomolecules |
| SG11201507046UA (en) | 2013-03-15 | 2015-10-29 | Nusirt Sciences Inc | Leucine and nicotinic acid reduces lipid levels |
| GB201313465D0 (en) | 2013-07-29 | 2013-09-11 | Queens University Of The Belfast | Methods of preparing nicotinamide riboside and derivatives thereof |
| WO2015061512A1 (en) | 2013-10-24 | 2015-04-30 | The Procter & Gamble Company | Skin lightening cosmetic compositions and methods |
| WO2015064988A1 (ko) | 2013-10-29 | 2015-05-07 | 한림대학교 산학협력단 | 니코틴아마이드 라이보사이드를 유효성분으로 포함하는 패혈증 치료 또는 예방용 약제학적 조성물 |
| JP6509844B2 (ja) | 2013-10-30 | 2019-05-08 | クロマデックス, インコーポレイテッドChromaDex, Inc. | 皮膚症状の治療において局所使用されるニコチンアミドリボシド組成物 |
| BR112016010422B1 (pt) | 2013-11-12 | 2021-08-31 | Ortho-Nutra, Llc | Suplemento dietético e método de tratamento para melhorar o desempenho ou energia física em um indivíduo |
| WO2015099842A1 (en) | 2013-12-23 | 2015-07-02 | Abbott Laboratories | Hot beverage fortifier |
| JP2017511304A (ja) | 2014-03-13 | 2017-04-20 | ソーク インスティチュート フォー バイオロジカル スタディーズ | フェキサラミン類似体ならびに作製方法および使用方法 |
| US20150297508A1 (en) | 2014-04-21 | 2015-10-22 | William Andriette | Topical Formulation to Enhance Genital Sensation and Function |
| WO2016011360A1 (en) | 2014-07-17 | 2016-01-21 | The Scripps Research Institute | Methods and compositions for enhancing cancer therapy |
| CN109562104A (zh) | 2016-04-14 | 2019-04-02 | 可劳迈戴斯有限公司 | 烟酰胺核苷、烟酸核苷、烟酰胺单核苷酸、和烟碱基化合物衍生物在婴儿配方中的用途 |
| NZ803738A (en) | 2016-11-11 | 2024-05-31 | Chromadex Inc | Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof |
| EP3727400A4 (en) | 2017-12-22 | 2021-10-20 | Elysium Health, Inc. | CRYSTALLINE FORMS OF NICOTINAMIDE RIBOSIDE CHLORIDE |
| JP7675061B2 (ja) | 2019-07-19 | 2025-05-12 | バイオシント アクチェンゲゼルシャフト | ニコチンアミドリボフラノシド塩の製造方法、ニコチンアミドリボフラノシド塩自体、およびその使用 |
| CN111808156A (zh) | 2020-07-15 | 2020-10-23 | 许昌远志生物科技有限公司 | 一种β-烟酰胺核糖氯化物的晶型1A、晶型1B及其制备方法 |
-
2018
- 2018-12-20 EP EP18892817.0A patent/EP3727400A4/en not_active Withdrawn
- 2018-12-20 WO PCT/US2018/066769 patent/WO2019126482A1/en not_active Ceased
- 2018-12-20 US US16/955,412 patent/US11414407B2/en active Active
- 2018-12-20 CN CN201880090063.7A patent/CN112020363A/zh active Pending
- 2018-12-20 JP JP2020534265A patent/JP2021506898A/ja active Pending
- 2018-12-20 CA CA3086535A patent/CA3086535A1/en active Pending
-
2022
- 2022-08-12 US US17/887,060 patent/US12043616B2/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017518306A (ja) * | 2014-06-02 | 2017-07-06 | グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited | 結晶性β−D−ニコチンアミドリボシドの製造および使用 |
| WO2016014927A2 (en) * | 2014-07-24 | 2016-01-28 | W.R. Grace & Co.-Conn. | Crystalline form of nicotinamide riboside |
| US20170210774A1 (en) * | 2014-07-24 | 2017-07-27 | W. R. Grace & Co.-Conn. | Crystalline Form Of Nicotinamide Riboside |
| WO2016144660A1 (en) * | 2015-03-09 | 2016-09-15 | W.R. Grace & Co.-Conn. | Crystalline form of nicotinamide riboside |
| WO2017218580A1 (en) * | 2016-06-14 | 2017-12-21 | Rejuvenation Therapeutics Corporation | Synthetic methods for the preparation of nicotinamide riboside and related compounds |
Non-Patent Citations (1)
| Title |
|---|
| HIRAYAMA, N., 有機化合物結晶作製ハンドブック −原理とノウハウ−, JPN6011053065, 2008, pages 57 - 84, ISSN: 0005027909 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3727400A1 (en) | 2020-10-28 |
| WO2019126482A1 (en) | 2019-06-27 |
| CA3086535A1 (en) | 2019-06-27 |
| US11414407B2 (en) | 2022-08-16 |
| US12043616B2 (en) | 2024-07-23 |
| US20230063175A1 (en) | 2023-03-02 |
| CN112020363A (zh) | 2020-12-01 |
| US20210094936A1 (en) | 2021-04-01 |
| EP3727400A4 (en) | 2021-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11629163B2 (en) | Methods of synthesizing nicotinamide riboside | |
| US12043616B2 (en) | Crystalline forms of nicotinamide riboside chloride | |
| KR101691536B1 (ko) | 신규 fak 저해제를 유효성분으로 포함하는 방사선 민감성 증진용 조성물 | |
| JP2021105030A (ja) | ニコチンアミドリボシドの結晶形 | |
| RU2268732C2 (ru) | Способы лечения митохондриальных нарушений | |
| RU2121998C1 (ru) | Производные пиримидина, способ их получения, фармкомпозиция | |
| US20210290578A1 (en) | Mixture of fatty acids for use in the treatment of inflammatory pathologies | |
| JP6122862B2 (ja) | 1−(5,6−ジクロロ−1h−ベンゾ[d]イミダゾール−2−イル)−1h−ピラゾール−4−カルボン酸のメグルミン塩製剤 | |
| KR20180073582A (ko) | β-니코틴아미드 모노뉴클레오티드의 결정 형태 | |
| CZ302269B6 (cs) | Farmaceutický prostredek pro lécbu artropatií | |
| JP6289659B2 (ja) | 五環トリテルペン構造修飾化合物とその調製方法及び応用 | |
| JP7201688B2 (ja) | 置換テトラヒドロピランジヒドロチエノピリミジンおよびホスホジエステラーゼ阻害剤としてのそれらの使用 | |
| EA020198B1 (ru) | N-ацетил-(r)-(-)-3-(4-аминофенил)-2-метоксипропионовая кислота, содержащая ее фармацевтическая композиция, способ лечения | |
| JP7294734B2 (ja) | カリウムチャネル調節剤としての化合物ならびにその調製および応用 | |
| CN115944626A (zh) | 小分子化合物在制备抗缺氧或缺血再灌注损伤药物中的应用 | |
| JP2012530492A (ja) | 真皮細胞の発毛促進能を増大させるための方法および組成物 | |
| KR102957893B1 (ko) | 인디루빈 유도체 및 대사활성화제를 포함하는 탈모 방지 또는 발모 촉진용 조성물 | |
| CN113214097A (zh) | 治疗阿尔茨海默病的化合物 | |
| CN108368117B (zh) | 一种取代的咪唑并喹唑啉化合物及其药物组合物 | |
| DE60202345T2 (de) | 5-heteroatomsubstituierte Pyrazole | |
| DE60202184T2 (de) | 5-(Alkyliden-cycloalkyl)- und 5-(Alkyliden-heterocyclyl)-Pyrazole | |
| EP2538941A1 (en) | Pyrrolidine substituted flavones for the treatment of inflammatory disorders | |
| KR102599625B1 (ko) | 셀레늄 화합물을 유효성분으로 포함하는 항암제 스트레스를 받은 세포 제거용 조성물 | |
| JPH11505240A (ja) | 減量用薬剤 | |
| KR20210100259A (ko) | 3,4-디아미노-3-시클로부텐-1,2-디온 유도체를 포함하는 탈모의 예방 또는 치료용 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20201225 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20201225 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211006 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20211006 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220906 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230404 |